



**ASX ANNOUNCEMENT**

**25 November 2014**

## ***Cynata Listed Options Fully Underwritten***

**Melbourne, Australia; 25 November 2014:** Stem cell and regenerative medicine company, Cynata Therapeutics Ltd (ASX: CYP), announced today the completion of a transaction with sophisticated investors to underwrite the conversion of the Company's outstanding 31 December 2014 ASX: CYPO listed options.

Including options already exercised, this transaction ensures that the Company will receive gross proceeds of \$2.9 million. A total of 10,622,093 listed options remain outstanding and are the subject of the underwriting agreement.

In accordance with ASX Listing Rule 3.1.03, the Company advises that the underwriters are Ardroy Securities Pty Ltd, Nesoi Investment Management Limited and Mr Jackie Au Yeung. The underwriters, who are not related parties of the Company, are to be paid an underwriting fee of 2%, for a total aggregate consideration of \$42,488.

Listed option holders are eligible to exercise their options up to 5.00 pm WST on 31 December 2014.

**Media contacts:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.